Living

US FDA declines to approve Cingulate's ADHD drug

By Reuters Reuters
FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo
FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo Andrew Kelly Reuters

Cingulate said on Tuesday that the U.S. Food and Drug Administration declined to approve its drug to treat attention deficit hyperactivity disorder.

(Reporting by Kunal Das and Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)

Copyright Reuters or USA Today Network via Reuters Connect

This story was originally published June 2, 2026 at 5:08 AM.

Get one year of unlimited digital access for $159.99
#ReadLocal

Only 44¢ per day

SUBSCRIBE NOW